Review By | Apply | May Apply | Neutral | Avoid | Not Rated |
---|---|---|---|---|---|
Count | 0 | 0 | 0 | 0 | 0 |
% | 0 | 0 | 0 | 0 | 0 |
[Dilip Davda] MHL is engaged in trading and manufacturing of pharma/healthcare products. It posted growth in its top and bottom lines for the reported periods. Quantum jump in bottom lines from FY24 raise eyebrows and concern over its sustainability, as it is operating in a highly competitive and fragmented segment. Based on recent financial data, the issue appears fully priced. Well-informed investors may park moderate funds for medium term, post doing their own due diligence. Read detail review...
Medistep Healthcare Ltd. peer comparison with similar listed entities. (As on March 31, 2025)
Company Name | EPS (Basic) | EPS (Diluted) | NAV (per share) (Rs) | P/E (x) | RoNW (%) | P/BV Ratio | Financial statements |
---|---|---|---|---|---|---|---|
Medistep Healthcare Limited | 4.01 | 4.01 | 16.28 | 10.72 | 24.62 | Standalone | |
Fabino Enterprises Limited | 0.63 | 0.63 | 20.42 | 41.27 | 3.12 | 1.30 | Standalone |
Achyut Healthcare Ltd | 0.02 | 0.02 | 1.33 | 209.00 | 1.77 | 4.00 | Standalone |
Source: The Company’s Financial Figures are based on restated standalone audited financial statements for Financial Year 2024-25. With respect to Industry peers, all the financial information mentioned above is on a standalone basis and is sourced from the audited results of the respective companies for the year ended March 31, 2025 unless provided otherwise.
Notes for peer group:
Medistep Healthcare IPO Reviews, analysis and views by popular members. Read Medistep Healthcare Ltd. IPO reviews by retail investors to find recommended ipo to buy.
Review By | Apply | May Apply | Neutral | Avoid |
---|---|---|---|---|
Count | 0 | 0 | 0 | 0 |
% | 0.00 | 0.00 | 0.00 | 0.00 |
Member | Review |
---|---|
No recommendation found. Be the first to post the recommendation. |
Post Recommendation Manage Recommendations
Note:
Useful Articles